Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amarin Is Prepared To Be ‘Aggressive’ With Vascepa Authorized Generic

Originator Restructures And Names New CEO Following Icosapent Ethyl Competition

Executive Summary

Amarin’s management has suggested that it would be prepared to compete “very aggressively” with a US authorized generic version of its Vascepa if and when it decides to launch. The comments came as the originator named a new CEO and restructured in the wake of increasing generic competition.

You may also be interested in...



Amneal Taps Strides To Add More Competition To US Vascepa Market

Amneal has in-licensed Strides’ generic version of Vascepa to compete with the several ANDA products already on the market.

Finance Watch: FibroGen, Amarin And Others Downsize To Survive

Restructuring Edition: FibroGen follows its clinical setback with a 32% reduction in force, cutting 104 jobs. Also, Amarin named a new CEO, but cut all US sales and 30% of non-sales US roles, and 9 Meters is headed for dissolution after Chapter 7 bankruptcy, while several others seek strategic alternatives.

Hikma Slams Amarin In Vascepa Antitrust Suit For ‘Locking Up API Supply’

Amarin is facing up to another antitrust lawsuit over its alleged control of API supply for its Vascepa brand.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152860

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel